Harrow Health, Inc. (NASDAQ:HROW – Get Rating ) Director Horn R. Lawrence Wan bought 1,860 shares of the firm’s stock in a transaction on Thursday, December 22nd. The shares were acquired at an average price of $13.42 per share, with a total value of $24,961.20. Following the completion of the transaction, the director now directly owns 1,860 shares of the company’s stock, valued at $24,961.20. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Harrow Health Stock Performance

Shares of NASDAQ HROW opened at $13.49 on Friday. The business’s 50-day simple moving average is $11.68, and the 200-day simple moving average is $9.44. The company has a debt-to-equity ratio of 83.80, a quick earnings ratio of 3.20, and a current ratio of 3.49. Harrow Health, Inc. it has a 52-week low of $5.40 and a 52-week high of $13.90. The firm has a market cap of $365.17 million, a price-to-earnings ratio of -16.25 and a beta of 0.36.

Institutional investors are gauging Harrow’s health

A number of large investors have recently added to or reduced their stakes in HROW. Tower Research Capital LLC TRC lifted its position in shares of Harrow Health by 530.7% during the third quarter. Tower Research Capital LLC TRC now owns 2,756 shares of the company’s stock valued at $33,000 after purchasing an additional 2,319 shares during the period. Barclays PLC boosted its stake in shares of Harrow Health by 44.3% in the third quarter. Barclays PLC now owns 3,560 shares of the company’s stock valued at $43,000 after purchasing an additional 1,093 shares during the period. Captrust Financial Advisors purchased a new stake in Harrow Health in the second quarter valued at approximately $51,000. Envestnet Asset Management Inc. acquired a new stake in Harrow Health in the first quarter valued at approximately $70,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Harrow Health in the second quarter valued at approximately $78,000. The institutional investors own 56.47% of the company’s stock.

Changes in analyst ratings

Separately, B. Riley started coverage on shares of Harrow Health in a research note on Thursday, September 8th. They issued a “buy” rating and a $17.00 target price for the company.

Harrow Health Company Profile

(Get Rating)

Harrow Health, Inc operates as a healthcare company focused on ophthalmology. The company owns ImprimisRx, an ophthalmology and pharmaceutical compounding outsourcing business. The Company also owns an equity interest in Surface Ophthalmics, Inc, a clinical pharmaceutical company focused on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical pharmaceutical company focused on the development and commercialization of proprietary non-intravenous, sedative and anesthetic therapeutics for human medical procedures in hospital, outpatient and office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company engaged in the development and commercialization of medicinal products.

Featured stories

This instant news alert is generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Harrow Health, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients daily. MarketBeat identified the five stocks top analysts are quietly whispering to their clients to buy now, before the broader market takes a nosedive … and Harrow Health wasn’t on the list.

While Harrow Health currently has a “Buy” rating among analysts, the top-rated analysts think these five stocks are better buys.

Check out the five stocks here

20 shares for sale now

MarketBeat just published its list of 20 stocks that Wall Street analysts hatred. These companies may appear to have good fundamentals, but the best analysts smell something seriously rotten. Are there any of these companies lurking around your portfolio? Find out by entering your email address below.

Get this free report

20 stocks for sale now Cover

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *